Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Trine Trab, Iman Chanchiri, Ahmed Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Michael Roost Clausen, Thomas Stauffer Larsen, Andriette C Desseau-Arp, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2024-201293

Published: 2024

Journal Articles

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Kossi D Abalo, Trine Trap, Joachim Baech, Sara Ekberg, Simon Pahnke, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Peter Brown, Thomas Stauffer Larsen, Kirsten Gronbaek, Tarec Christoffer El-Galaly, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2024-206964

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2024) 144 (Supplement 1): 650.

https://doi.org/10.1182/blood-2024-201672

Published: 2024

Journal Articles

Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Peter Brændstrup, Thomas Bech Mortensen, Tarec Christoffer El-Galaly, Michael Boe Møller, Judit Mészáros Joergensen, Christian Bjørn Poulsen, Peter de Nully Brown, Dennis Lund Hansen, Thomas Stauffer Larsen

Blood (2024) 144 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2024-199691

Published: 2024

Journal Articles

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Johannes Duell, Diana Alvarez Arias, Hilka Rauert-Wunderlich, Florian Eisele, Alla Volgina, Beth Rumberger, Thomas Stauffer Larsen, Andreas Rosenwald

Blood (2024) 144 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2024-199176

Published: 2024

Journal Articles

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Emil Ramsø Kyvsgaard, Morten Grauslund, Lene Sjö, Linea Melchior, Trine Grantzau, Lise Mette Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Fredslund Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Gronbaek, Martin Hutchings, Simon Husby

Blood (2024) 144 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2024-204772

Published: 2024

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2023) 142 (Supplement 1): 190.

https://doi.org/10.1182/blood-2023-182606

Published: 2023

Journal Articles

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Blood (2023) 142 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2023-184367

Published: 2023

Journal Articles

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Freja Tang Severinsen, Laura Mors Haunstrup, Rasmus Kuhr Jensen, Matthew J. Maurer, Arushi Khurana, Paw Jensen, Judit M. Jørgensen, Thomas Stauffer Larsen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Lasse H. Jakobsen

Blood (2021) 138 (Supplement 1): 53.

https://doi.org/10.1182/blood-2021-151100

Published: 2021

Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti

Blood (2021) 138 (Supplement 1): 525.

https://doi.org/10.1182/blood-2021-148359

Published: 2021

Journal Articles

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Simon Husby, Gustav Ørting Jørgensen, Francesco Favero, Jakob Schmidt Jespersen, German G.R. Gonzalez, Christian Nielsen, Betina Sørensen, Lene Hyldahl Ebbesen, John Bæch, Eva Kannik Hastrup, Pär L. Josefsson, Michael Thorsgaard, Tarec Christoffer El-Galaly, Peter de Nully Brown, Thomas Stauffer Larsen, Joachim Weisenfeldt, Kirsten Grønbæk

Blood (2021) 138 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2021-145417

Published: 2021

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 2978.

https://doi.org/10.1182/blood-2019-131698

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2018-99-110602

Published: 2018

Journal Articles

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Jorne Lionel Biccler, MSc, BSc, Kerry J Savage, BSc, MD MSc, Peter de Nully Brown, MD PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Christian Bjørn Poulsen, MD, Danny Stoltenberg, MD, Lasse H. Jakobsen, Martin Bøgsted, Professor, Diego Villa, MD, Tarec C. El-Galaly

Blood (2018) 132 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2018-99-114191

Published: 2018

NARROW

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only